Hims & Hers Health (NYSE:HIMS) PT Raised to $25.00 at Bank of America

Hims & Hers Health (NYSE:HIMS) had its price target boosted by Bank of America from $23.00 to $25.00 in a report published on Monday, Benzinga reports. They currently have a buy rating on the stock.

Other research analysts have also recently issued research reports about the company. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective on the stock. Jefferies Financial Group raised their price objective on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, June 27th. Finally, Truist Financial upped their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Eight research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $20.21.

Hims & Hers Health Trading Up 0.7 %

Shares of Hims & Hers Health stock opened at $21.52 on Monday. Hims & Hers Health has a 12 month low of $5.65 and a 12 month high of $25.74. The firm has a market capitalization of $4.62 billion, a P/E ratio of 269.03 and a beta of 1.06. The business has a fifty day simple moving average of $17.36 and a two-hundred day simple moving average of $17.76.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The company had revenue of $315.65 million during the quarter, compared to analysts’ expectations of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. Hims & Hers Health’s revenue was up 51.8% on a year-over-year basis. During the same period last year, the company posted ($0.03) EPS. Analysts predict that Hims & Hers Health will post 0.22 earnings per share for the current year.

Insider Activity

In other Hims & Hers Health news, insider Michael Chi sold 7,500 shares of the firm’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $22.20, for a total value of $166,500.00. Following the transaction, the insider now directly owns 193,980 shares of the company’s stock, valued at approximately $4,306,356. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Soleil Boughton sold 2,334 shares of the business’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $17.30, for a total transaction of $40,378.20. Following the completion of the sale, the insider now owns 164,475 shares of the company’s stock, valued at $2,845,417.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Michael Chi sold 7,500 shares of the firm’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $22.20, for a total value of $166,500.00. Following the completion of the transaction, the insider now directly owns 193,980 shares in the company, valued at approximately $4,306,356. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 841,076 shares of company stock valued at $14,759,219 in the last ninety days. 17.71% of the stock is currently owned by company insiders.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Carnegie Investment Counsel purchased a new position in shares of Hims & Hers Health during the 3rd quarter valued at about $5,531,000. Diversify Advisory Services LLC bought a new position in shares of Hims & Hers Health in the first quarter worth approximately $701,000. Sei Investments Co. increased its stake in shares of Hims & Hers Health by 206.9% in the first quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after purchasing an additional 37,890 shares in the last quarter. Quantbot Technologies LP raised its position in shares of Hims & Hers Health by 3,444.9% during the 1st quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock valued at $3,321,000 after purchasing an additional 208,621 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its stake in shares of Hims & Hers Health by 164.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after buying an additional 328,142 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.